Tirzepatide

5mg Vial

10mg Vial

15mg Vial

20mg Vial

30mg Vial

40mg Vial

50mg Vial

60mg Vial

29 August 2026Updated 29 August 2026

Tirzepatide

Overview Research0 Mechanism Protocols Safety

Discussions

This is Premium content Premium

Create a free account, then upgrade to Premium or Lifetime to unlock the full research article, mechanism of action, results timeline, dosing protocol, and dose calculator for Tirzepatide.

Create free account Member login

Full range of benefits for Tirzepatide

Lowers HbA1c in clinical trials for type 2 diabetes

Associated with substantial weight loss in randomized studies

Decreases fasting and postprandial glucose concentrations

Enhances glucose-dependent insulin secretion

May improve insulin sensitivity and glycemic variability

Reduces appetite and overall caloric intake

Slows gastric emptying, influencing post-meal glucose levels

Associated with reductions in liver fat in NAFLD studies

May improve cardiometabolic markers such as BP and triglycerides

Associated with reductions in body fat and waist circumference

May help preserve or improve pancreatic beta-cell function

Demonstrates durable glycemic control in longer-term studies

This peptide's combination-safety and interaction data below always stays visible, regardless of membership.

Warning

Important information. The data compiled from scientific literature is provided for educational purposes. Dosage ranges reflect what is reported in studies and do not constitute a recommendation, prescription, or usage guidance. Health decisions should always be made with a qualified professional.

Peptide Interactions

// 15 known interactions

Synergistic(3)Compatible(3)Monitor(5)Avoid(4)

Works exceptionally well with this peptide

Metformin

Complementary first-line oral agent that enhances tirzepatide's glycaemic efficacy and weight-reduction effects when used together.

SGLT2 inhibitors (e.g., empagliflozin, dapagliflozin)

Provides additive glucose-lowering and cardiorenal benefits and can augment weight loss when combined with tirzepatide.

GLP-1/dual agon supportive lifestyle therapy (structured diet and exercise programs)

Non-pharmacologic interventions synergise with tirzepatide to maximise glycaemic control and weight-loss outcomes.

All interaction categories

Synergistic (3)

Metformin: Complementary first-line oral agent that enhances tirzepatide's glycaemic efficacy and weight-reduction effects when used together.
SGLT2 inhibitors (e.g., empagliflozin, dapagliflozin): Provides additive glucose-lowering and cardiorenal benefits and can augment weight loss when combined with tirzepatide.
GLP-1/dual agon supportive lifestyle therapy (structured diet and exercise programs): Non-pharmacologic interventions synergise with tirzepatide to maximise glycaemic control and weight-loss outcomes.

Compatible (3)

Statins (e.g., atorvastatin): No direct pharmacokinetic interaction expected; routinely co-administered for cardiovascular risk management.
ACE inhibitors / ARBs (e.g., ramipril, losartan): Antihypertensive agents with neutral interaction profile that can be continued without dose adjustment for tirzepatide.
Proton pump inhibitors (e.g., omeprazole): Generally compatible with tirzepatide, with no clinically significant interaction expected.

Monitor (5)

Insulin (basal and prandial): Requires frequent glucose monitoring and likely dose reductions because tirzepatide improves glycaemic control and increases hypoglycaemia risk.
Sulfonylureas (e.g., glibenclamide, glimepiride): Increased risk of hypoglycaemia when combined with tirzepatide, warranting dose adjustment and close glucose monitoring.
Warfarin (vitamin K antagonists): Delayed gastric emptying and weight changes may unpredictably alter INR, so monitor INR after initiation or dose changes of tirzepatide.
Oral contraceptives (combined oral contraceptives): Delayed gastric emptying can reduce absorption of some oral contraceptives; counsel patients and monitor for reduced efficacy or consider alternative methods if concerned.
Levothyroxine: Gastric emptying changes may affect oral levothyroxine absorption, so monitor TSH and adjust dose if clinically indicated.

Avoid (4)

GLP-1 receptor agonists (e.g., semaglutide, exenatide): Overlapping incretin mechanisms offer little additional benefit and increase gastrointestinal adverse effects, so combination should be carefully justified or avoided.
Opioids and anticholinergic agents (e.g., oxycodone, hyoscine): These agents further slow gastric motility and can exacerbate nausea, vomiting or impair absorption of oral medications when used with tirzepatide.
DPP-4 inhibitors (e.g., sitagliptin): Little additive glycaemic benefit and theoretical concerns about overlapping incretin pathway effects (including rare reports of pancreatitis) mean combination should be used with caution.
Drugs with a narrow therapeutic index absorbed orally (e.g., phenytoin, certain anticoagulants): Delayed gastric emptying and weight changes may unpredictably alter oral absorption and exposure, so risk–benefit and monitoring should be assessed before co-administration.